Polymer-Modified IL-2 Polypeptides for Selective IL-2Rβ Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies for cancer treatment are limited by toxicities such as vascular leak syndrome and short half-life, necessitating frequent dosing, and lack selectivity for different IL-2 receptor subunits.
Innovation Solution
Development of modified IL-2 polypeptides with covalently attached polymers, particularly at residue F42Y, exhibiting enhanced affinity and selectivity for IL-2Rβ over IL-2Rα, thereby reducing binding to IL-2Rα and extending half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-2 is used to treat cancer, then immune system activation is improved, but toxicities such as vascular leak syndrome increase
Solution Approach 1:
The patent applies local quality by modifying specific amino acid residues in the IL-2 polypeptide (e.g., F42Y mutation) to alter its binding characteristics. This localized modification changes how IL-2 interacts with different receptor subunits, enhancing selectivity for IL-2Rβγ while reducing binding to IL-2Rα, thereby activating the immune system against cancer while minimizing toxic side effects like vascular leak syndrome.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular structure of IL-2 through amino acid substitutions and polymer conjugation. These structural parameter changes result in altered binding affinity parameters, specifically increasing selectivity for IL-2Rβγ over IL-2Rα, which transforms the therapeutic profile to reduce toxicities while maintaining or enhancing anti-tumor efficacy.
2Reliability
If IL-2 is administered frequently to maintain therapeutic levels, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-conjugating polymer chains to the IL-2 polypeptide during manufacturing. This preliminary modification extends the half-life of IL-2 in vivo, allowing the drug to maintain therapeutic levels for longer periods. As a result, the dosing frequency can be reduced from three times per day to less frequent administrations, simplifying the treatment regimen while maintaining efficacy.
3Reliability
If IL-2 binds to IL-2Rα, then immune regulation is improved, but selectivity for IL-2Rβγ is reduced
Solution Approach 1:
The patent applies local quality by introducing specific amino acid mutations at key positions in the IL-2 molecule (such as F42Y) that locally alter the binding interface. This localized modification selectively enhances affinity for IL-2Rβγ while reducing binding to IL-2Rα, achieving differential selectivity that allows the drug to preferentially activate cytotoxic immune cells over regulatory T cells, thereby improving both selectivity and immune regulation.
Data Source
AI summary
The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor βγ complex (IL-2Rβ) over IL-2 receptor αβγ complex (IL-2Rα). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.